Ingo Bernhard Runnebaum - Gynecology

Author Information

Dr. Ingo Bernhard Runnebaum is affiliated with the Department of Gynecology and Reproduction Medicine at Jena University Hospital, Friedrich Schiller University Jena, located in Jena, Germany. His research focuses primarily on gynecologic oncology, particularly in ovarian and cervical cancers.

Research Contributions

Dr. Runnebaum has made significant contributions to the field of gynecology and oncology. His recent work includes studies on polygenic risk modeling for ovarian cancer, genome-wide association studies identifying risk loci for cervical cancer, and the synthesis and characterization of platinum complexes. His research often explores the genetic and molecular mechanisms underpinning cancer risk and treatment responses, aiming to improve diagnostic and therapeutic strategies for gynecologic malignancies.

Aliases

Dr. Ingo Bernhard Runnebaum is also known by several aliases, including Ingo B. Runnebaum, I B Runnebaum, Ingo Runnebaum, and other variations. These aliases are often used interchangeably in academic publications.

Publication and Citation Metrics

Metric	Value
Citation Count	7,652
h-index	42
Paper Count	209

Publications:

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

DOI: 10.1038/s41431-022-01085-y

Year: 2022

Genome-wide association study and functional follow-up identifies 14q12 as a candidate risk locus for cervical cancer.

DOI: 10.1093/hmg/ddac031

Year: 2022

Synthesis and characterization of thiocarbonato-linked platinum(IV) complexes.

DOI: 10.1039/d2dt00318j

Year: 2022

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

DOI: 10.1038/s41431-021-00987-7

Year: 2022

Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance

DOI: 10.3390/cancers13133309

Year: 2021

RUNX3 Transcript Variants Have Distinct Roles in Ovarian Carcinoma and Differently Influence Platinum Sensitivity and Angiogenesis

DOI: 10.3390/cancers13030476

Year: 2021

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

DOI: 10.1016/s0090-8258(21)00695-8

Year: 2021

CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

DOI: 10.1186/s13148-021-01006-8

Year: 2021

Association of genomic variants at PAX8 and PBX2 with cervical cancer risk

DOI: 10.1002/ijc.33614

Year: 2021

ITIH5 shows tumor suppressive properties in cervical cancer cells grown as multicellular tumor spheroids.

DOI:

Year: 2021

What is the role of artificial intelligence (AI) in Gynecology?

Why Do Uterine Contractions Occur?

How is Gallbladder Disease Diagnosed?

What are the Post-Procedure Considerations?

How Long Does the Transition Phase Last?

What is Medical Billing and Coding?

Why Does Chadwick's Sign Occur?

Can Simulation Be Used for Team Training?

How Often Should Blood Pressure be Monitored?

What Role Does Polycystic Ovary Syndrome (PCOS) Play in Weight Gain?

Partnered Content Networks

Relevant Topics